The ability of these compounds to disrupt the interaction between E6 and critical tumor suppressors, like TP-53 and pRb, could lead to the development of novel therapeutic protocols aimed at preventing or treating HPV-induced malignancies. The gene discussed is RB1; the disease is neoplasm.